FDA Recall Highlights Ongoing Risks of Adulterated “Sexual Enhancement” Supplements
Pure Vitamins and Natural Supplements, LLC (Tampa, FL) has issued a voluntary nationwide recall of several honey-based dietary supplement products after FDA laboratory testing detected undeclared prescription drug ingredients.
The recalled products include Boner Bear Honey, Red Bull Extreme, and Blue Bull Extreme
According to the company announcement, FDA laboratory analysis confirmed the presence of sildenafil and tadalafil, the active ingredients in the prescription drugs Viagra® and Cialis®, respectively. These medications are approved only for use under the supervision of a licensed healthcare provider for the treatment of erectile dysfunction.
Because the ingredients were not declared on product labeling, the products are considered adulterated and potentially dangerous. Sildenafil and tadalafil can interact with nitrate medications such as nitroglycerin, potentially causing dangerous drops in blood pressure, particularly in patients with cardiovascular disease, diabetes, or hypertension.
The products were marketed as single-serve “sexual enhancement honey” supplements packaged in plastic tubes. No adverse events have been reported to date.
Consumers are advised to discontinue use and return the products for a refund.
Links
Click here to see the recall notice.
Intersurgical 22mm Smoothbore Breathing Tubes and Systems
FDA Issues Early Alert for Intersurgical Breathing Systems Over Potential Ventilation Failure. Manufacturing defect may cause breathing tube connectors to separate during use, potentially interrupting ventilation and exposing patients to serious injury or death.The...
FDA Early Alert: Teleflex/Arrow Guidewire
Affected guidewires and catheter products may release hydrophilic polymer particles into the bloodstream, potentially causing serious injury or death. No serious injuries or deaths have been reported.The U.S. Food and Drug Administration (FDA) has issued an Early...
FDA Investigates Cancer Risk with Zolgensma Gene Therapy
Postmarketing reports identify cases of tumor formation linked to gene therapy vector integration, prompting FDA to evaluate potential regulatory action.The U.S. Food and Drug Administration (FDA) is investigating a serious potential cancer risk associated with...
Eugia Vancomycin Recall: Glass Particle Contamination
FDA announces voluntary recall of a single lot of vancomycin hydrochloride for injection because of potentially dangerous particulate contamination.Eugia US LLC, formerly Auro Medics Pharma LLC, has initiated a voluntary nationwide recall of one lot of Vancomycin...
FDA Requires New GLP-1 Drug Warning for Vision Loss Risk
Agency cites potential increased risk of rare optic nerve condition following review of clinical trials and postmarket safety dataThe U.S. Food and Drug Administration (FDA) is requiring manufacturers of all glucagon-like peptide-1 receptor agonist (GLP-1 RA)...
Class 1 Recall for HemosIL AcuStar HIT Antibody Test
HemosIL AcuStar HIT-IgG(PF4-H). Source: fda.govPerformance problems could produce false-negative results, potentially delaying diagnosis of a dangerous reaction to heparin.The U.S. Food and Drug Administration (FDA) has identified a recall of certain lots of the...